CTOs on the Move

Zymergen

www.zymergen.com

 
Founded in 2013 and based in the San Francisco Bay Area, Zymergen integrates automation, machine learning, and genomics to rapidly accelerate the pace of scientific advancement. We treat the genome as a search space, leveraging machine learning to make discoveries far beyond the bounds of human intuition. In doing so, we deliver economic value, material diversity and performance capabilities not previously possible.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.zymergen.com
  • 5980 Horton Street Suite 105
    Emeryville, CA USA 94608
  • Phone: 415.801.8073

Executives

Name Title Contact Details
Dmitriy Ryaboy
Chief Technology Officer Profile

Funding

Zymergen raised $44M on 06/16/2015
Zymergen raised $130M on 10/11/2016
Zymergen raised $400M on 12/13/2018
Zymergen raised $300M on 09/08/2020

Similar Companies

Divergence

Divergence is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alpine Immune Sciences

Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat autoimmune and inflammatory diseases. We have two products in the clinic for inflammatory diseases, collaborations with world-class partners, and a robust development pipeline. Traded on NASDAQ under ticker ALPN.

Notch Therapeutics

Notch is an immune cell therapy company developing a next-generation pipeline of off-the-shelf, universally compatible, genetically tailored T cell therapeutics derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.

Vizgen

Vizgen is unlocking the power of spatial biomolecule profiling to bring new insight into biological systems and disease.

Notable Labs

Notable Labs is a translationally focused drug development company that uses a clinically validated, automated compound sensitivity platform to identify and advance novel therapeutic candidates to dramatically reduce the cost and time of the traditional drug development process.